DISCOVERY OF PARASITE-DERIVED TOLEROGENIC ADJUVANTS

寄生虫源致耐受佐剂的发现

• 批准号: 10017567
• 负责人: PAUL GUYRE
• 金额: $ 59.92万
• 依托单位: CELDARA MEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-16 至 2021-08-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10017567
• 关键词: Adjuvant; Autoimmune Diseases; Brugia malayi; Cells; Disease; Helminths; Human; In Vitro; Insulin-Dependent Diabetes Mellitus; Lymphocyte; Mediating; Parasites; Patients; Property; Proteins; Testing; Th2 Cells; Vaccines; autoreactivity; bioinformatics tool; effector T cell; immunoregulation; monocyte; screening; secretory protein

Parasitic helminths express proteins with immunomodulatory/tolerogenic properties to assure long-term survival in their host. The objective of the project is to identify worm proteins that can be used as adjuvants for disease-modifying adjuvants in vaccines against autoimmune diseases such as Type 1 Diabetes, by downregulating effector T cells, stimulating Th2 cells, or inducing regulatory lymphocytes.

寄生蠕虫表达具有免疫调节/耐受特性的蛋白质，以确保在宿主体内长期生存。该项目的目标是确定蠕虫蛋白，通过下调效应 T 细胞、刺激 Th2 细胞或诱导调节性淋巴细胞，可将其用作 1 型糖尿病等自身免疫性疾病疫苗中疾病修饰佐剂的佐剂。